Daiichi Sankyo Company, Limited · TSE:4568

Daiichi Sankyo — Q2 FY2014 Earnings Presentation

25 slides from Daiichi Sankyo's earnings presentation, Nov 4, 2014

  1. Slide 1: Top Management Presentation

    Top Management Presentation Financial Results for 2Q FY2014 (April 1 – September 30, 2014) Joji Nakayama President and CEO November 4, 2014 0

  2. Slide 2: Today's Topics

    Today’s Topics  FY2014 2Q Results  FY2014 revised consolidated forecast  Business Update  Optimization of Business Operation Structure in Japan  R&D Update 1

  3. Slide 3: FY2014 2Q Results

    O Daiichi-Sankyo FY 2014 2Q Results

  4. Slide 4: Overview of FY2014 2Q Results

    Overview of FY2014 2Q Results Consolidated Statement of Profit or Loss Daiichi Sankyo Group JPY Bn JPY Bn FY2013 FY2014 FY2013 FY2014 Revised YoY YoY 2Q Result 2Q Result 2Q Result 2Q Result Plan* +0.1% 920.0 Revenue 516.8 525.4 +8.6 Revenue 429.1 429.6 +0.5 900.0 Cost of sales 174.1 176.1 +2.1 Cost

  5. Slide 5: FY2014 2Q Revenue

    FY2014 2Q Revenue (JPY Bn) Positive Factors Negative Factors Decline in Japan and Daiichi Sankyo Inc. offsetted by growth of Luitopold and ASCA Consolidated Statement of Profit or Loss Daiichi Sankyo Group 400.0 410.0 420.0 430.0 500.0 510.0 520.0 530.0 FY2013 Q2 Results 429.1 FY2013 Q2 Results 516.

  6. Slide 6: FY2014 2Q Operating Profit

    FY2014 2Q Operating Profit Positive Factors Negative Factors (JPY Bn) Operating profit increase reflected decreases in SG&A expenses and R&D expenses Consolidated Statement of Profit or Loss Daiichi Sankyo Group 40.0 50.0 60.0 70.0 20.0 30.0 40.0 50.0 60.0 FY2013 Q2 Results 52.7 FY2013 Q2 Results 50

  7. Slide 7: FY2014 2Q Profit attributable to owners of the Company

    FY2013 1Q Profit attributable to Positive Negative owners of the Company (JPY Bn) Factors Factors Profit (attributable to owners of the Company) increase owing to the operating profit increase and an improvement in financial income/expenses Consolidated Statement of Profit or Loss Daiichi Sankyo Gro

  8. Slide 8: FY2014 revised consolidated forecast

    FY2014 revised consolidated forecast

  9. Slide 9: FY2014 revised consolidated forecast

    FY2014 revised consolidated forecast JPY Bn FY 2013 FY 2013 Forecast Revised Forecast change (July) (October) Revenue 920.0 900.0 -20.0 Cost of sales 285.0 280.0 -5.0 R&D expenses 182.0 182.0 0 SG&A expenses 333.0 338.0 +5.0 Operating Profit 120.0 100.0 -20.0 Profit before tax 120.0 100.0 -20.0 Prof

  10. Slide 10: Summary of the revised FY2014 forecast

    Summary of the revised FY2014 forecast Sales growth of mainstay products in Japan at a rate below initial forecasts, Sales decline of long listed products at a greater rate than initially Revenue forecasted as a result of expansion in prescriptions of generic products, Intensified price competition

  11. Slide 11: Business Update

    O Daiichi-Sankyo Business Update

  12. Slide 12: Major Products in Japan

    Major Products in Japan JPY Bn Revised 2013Q2 2014Q2 Result Result YoY Forecast Change To Plan (Oct.) Olmetec anti-hypertension 37.6 37.8 +0.3 79.0 48% anti-ulcer Nexium (Proton Pump Inhibitor) 24.0 32.1 +8.1 67.0 48% analgesic and anti- Loxonin inflammatory 30.7 25.4 -5.3 48.0 -4.0 53% treatment fo

  13. Slide 13: Initiatives for Mainstay Products in Japan

    Initiatives for Mainstay Products in Japan Olmetec  Use home blood pressure data  Emphasize appeal of excellent antihypertensive effect and consistency  Keep No. 1 ARB share ネキシウム Nexium  In 3rd year after launch, gain overwhelming market share through strong partnership with AstraZeneca  Promo

  14. Slide 14: Initiatives for Mainstay Products in Japan

    Initiatives for Mainstay Products in Japan Memary  Emphasize appeal of advancement suppression effects from combination with Donepezil  Steadily spread orally disintegrating (OD) tablet  Secure new prescriptions and provide continuous education on disease by clarifying symptoms Memary® is effecti

  15. Slide 15: Major Business Units

    Major Business Units JPY Bn Revised FY2013Q2 FY2014Q2 Result Result YoY Forecast Change To plan (Oct.) Japan Company + Vaccine business 227.6 222.6 -4.9 480.0 -28.0 46% Daiichi Sankyo Healthcare 23.0 22.7 - 0. 3 48.0 47% Daiichi Sankyo Inc. 86.5 78.1 -8.4 161.0 -3.0 49% Olmesartan 56.8 47.2 -9.6 98.

  16. Slide 16: Merger of Ranbaxy with Sun Pharma

    Merger of Ranbaxy with Sun Pharma  Agreements for a merger of Ranbaxy with Sun Pharma on April 6, 2014  Approved at the respective general shareholders’ meetings of Ranbaxy and Sun Pharma by September 30, 2014 • The final examinations by the relevant authorities are currently in progress • Daiichi

  17. Slide 17: Optimization of Business Operation Structure in Japan

    Optimization of Business Operation Structure in Japan

  18. Slide 18: Optimization of Business Operation Structure in Japan: Background and Aims

    Optimization of Business Operation Structure in Japan  Background • Improve SG&A ratio that is higher than industry standard • Handle Olmesartan patent period expiration* Optimization of Business Operation Structure in Japan  Aims • Strengthen business foundation to enable investment for sustainab

  19. Slide 19: Optimization of Business Operation Structure in Japan

    Optimization of Business Operation Structure in Japan  Reform business operation in each unit • Self-sustaining business operation in each Japan business • Greater efficiency through reduction of indirect operations and concentration of operations • Expediting of decision making through simplified

  20. Slide 20: R&D Update

    Daiichi-Sankyo R&D Update

  21. Slide 21: Progress in R&D pipeline

    Progress in R&D pipeline Major change from 1Q FY2014 announcement Generic Name Target indication region Ph-1 Ph-2 Ph-3 Filed Approved Dev. Code 2014年度 第1四半期決算発表からの主な変更点 Prevention of stroke and systemic embolism JP in patients with NVAF Edoxaban Treatment of DVT and prevention of recurrent JP VTE Mi

  22. Slide 22: CL-108: Hydrocodone combination

    CL-108: Hydrocodone combination  In-license product from Charleston Laboratories Inc.*  Exclusive license for commercialization in US  Hydrocodone**・acetaminophen・promethazine (immediate release) combination • To be used for managed care for patients with from mid to severe acute pain • Decrease

  23. Slide 23: AC220 / Quizartinib

    AC220 / Quizartinib  Acquired Ambit Bioscience by TOB  MOA:FLT3 (Fms-Like Tyrosine Kinase 3)-ITD*inhibitor (*ITD:Internal Tandem Duplication)  Target indication: FLT3-ITD mutation positive acute myeloid leukemia (AML) • FLT3-ITD mutation is observed in 30% of patients with AML, resulted in poor c

  24. Slide 24: Major R&D Pipeline

    Major R&D Pipeline As of October 2014 Therapeutic area Phase 1 Phase 2 Phase 3 Application  DS-1040  CS-3150 (JP)  Prasugrel (JP)  Edoxaban (US/EU/Others) (Acute ischemic stroke / TAFIa (Hypertensive / DM nephropathy / (CS-747 / ischemic stroke / anti- (DU-176b / AF / oral factor Xa inhibitor) C

  25. Slide 25: Contact: Corporate Communications Department

    Contact address regarding this material Daiichi Sankyo Co., Ltd. Corporate Communications Department TEL: +81-3-6225-1126 Financial forecasts, future projections and R&D information that Daiichi Sankyo discloses may include information that might be classified as “Forward Looking Statement”. These f

Daiichi Sankyo Company — Q2 FY2014 Earnings Presentation on 6ix